1103501-90-1 Usage
Uses
Used in Pharmaceutical Research:
(S)-6-aza-spiro[2.5]octan-4-ol is used as a building block for the development of new drug molecules and bioactive compounds. Its unique spiro-fused structure and chirality make it an attractive candidate for the creation of novel chemical entities with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-6-aza-spiro[2.5]octan-4-ol is utilized as a versatile starting material for the preparation of diverse chemical derivatives. Its stereochemistry and reactivity enable the synthesis of a wide range of compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Drug Discovery and Development:
(S)-6-aza-spiro[2.5]octan-4-ol's potential pharmacological properties make it a valuable asset in drug discovery and development. Researchers can leverage the unique structural features of (S)-6-aza-spiro[2.5]octan-4-ol to design and synthesize new drug candidates that may exhibit improved efficacy, selectivity, and safety profiles compared to existing treatments.
Used in Chemical Derivative Synthesis:
(S)-6-aza-spiro[2.5]octan-4-ol is employed as a starting material for the synthesis of various chemical derivatives. These derivatives can be further explored for their potential applications in different fields, such as pharmaceuticals, agrochemicals, and materials science, where they may contribute to the development of innovative products and technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 1103501-90-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,3,5,0 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1103501-90:
(9*1)+(8*1)+(7*0)+(6*3)+(5*5)+(4*0)+(3*1)+(2*9)+(1*0)=81
81 % 10 = 1
So 1103501-90-1 is a valid CAS Registry Number.
1103501-90-1Relevant academic research and scientific papers
DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS
-
Page/Page column 53-54, (2011/05/06)
The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
NOVEL HETEROCYCLYL COMPOUNDS
-
Page/Page column 21, (2010/02/17)
The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.
NOVEL HETEROCYCLYL COMPOUNDS
-
Page/Page column 20, (2010/02/17)
The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
HETEROCYCLIC COMPOUNDS
-
Page/Page column 21, (2009/02/11)
The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
